Literature DB >> 16751069

Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation.

Mitchell S Anscher1, Bradley Thrasher, Zahid Rabbani, Beverly Teicher, Zeljko Vujaskovic.   

Abstract

PURPOSE: The aim of this study was to determine whether a neutralizing transforming growth factor-beta (TGFbeta) antibody can prevent radiation (RT) induced lung injury. METHODS AND MATERIALS: Fractionated and sham right lung irradiation in Fischer 344 rats was delivered to assess the radioprotective effect of the antibodies. Animals were divided into the following groups: (1) control (sham RT, control antibody 13C4); (2) RT (800cGy x 5)+13C4); (3) RT + 0.1 mg/kg 1D11 anti-TGFbeta antibody; and (4) RT + 1 mg/kg 1D11 antibody. Antibodies were intraperitoneally administered immediately after the last fraction of RT. Animals were sacrificed at 6 and 26 weeks after irradiation. Lungs were assessed for histologic changes, activation of macrophages, expression/activation of TGFbeta and its signal transduction pathway.
RESULTS: At 6 weeks post-RT, there was a significant reduction in macrophage accumulation (p = 0.041), alveolar wall thickness (p = 0.0003), and TGF-beta activation (p = 0.032) in animals receiving 1.0 mg/kg 1D11 vs. in the control group. However, at 6 weeks, the low dose of 1D11 antibody (0.1 mg/kg) failed to produce any significant changes. At 6 months post-RT, radioprotection is apparent for the group receiving 1.0 mg/kg 1D11, with activated macrophages (p = 0.037), alveolar wall thickness (p = 0.0002), TGFbeta activation (p = 0.002) and its signal transduction proteins (p < 0.05) compared with the control group.
CONCLUSIONS: Administration of a single dose of 1.0 mg/kg of the anti-TGFbeta antibody 1D11 resulted in decreased morphologic changes, inflammatory response, and reduced expression and activation of TGFbeta 6 weeks and 6 months after 40 Gy to the right hemithorax. Targeting the TGFbeta pathway may be a useful strategy to prevent radiation-induced lung injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751069     DOI: 10.1016/j.ijrobp.2006.02.051

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  51 in total

Review 1.  Modifying radiation damage.

Authors:  Kwanghee Kim; William H McBride
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

2.  Linear attenuation coefficient and buildup factor of MCP-96 alloy for dose accuracy, beam collimation, and radiation protection.

Authors:  Deidre N Hopkins; Muhammad Maqbool; Mohammed S Islam
Journal:  Radiol Phys Technol       Date:  2012-05-15

Review 3.  Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders.

Authors:  Stephen L Nishimura
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

Review 4.  Effect of transforming growth factor-β1 869C/T polymorphism and radiation pneumonitis.

Authors:  Yingtian Wang; Xingguang Wang; Xiyan Wang; Deyong Zhang; Shujuan Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 5.  Treatment of Radiation Injury.

Authors:  Sadanori Akita
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-01-01       Impact factor: 4.730

Review 6.  Mechanisms of Normal Tissue Injury From Irradiation.

Authors:  Deborah E Citrin; James B Mitchell
Journal:  Semin Radiat Oncol       Date:  2017-10       Impact factor: 5.934

7.  A patient with Loeys-Dietz syndrome treated with chemoradiotherapy for an oropharyngeal carcinoma.

Authors:  Andrew K Chan; Daren Teoh; Paul Matthews; Lydia Fresco
Journal:  BMJ Case Rep       Date:  2013-09-17

Review 8.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

9.  Advances in targeting the transforming growth factor β1 signaling pathway in lung cancer radiotherapy.

Authors:  Zhonghua Lu; Yiting Tang; Judong Luo; Shuyu Zhang; Xifa Zhou; Lei Fu
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

10.  Halofuginone enhances the radiation sensitivity of human tumor cell lines.

Authors:  John A Cook; Rajani Choudhuri; William Degraff; Janet Gamson; James B Mitchell
Journal:  Cancer Lett       Date:  2009-08-26       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.